- Home
- KRO vs PVLA Comparison
KRO vs PVLA Comparison
Compare KRO & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRO
- PVLA
- Stock Information
- Founded
- KRO 1916
- PVLA 2015
- Country
- KRO United States
- PVLA United States
- Employees
- KRO N/A
- PVLA N/A
- Industry
- KRO Major Chemicals
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- KRO Industrials
- PVLA Health Care
- Exchange
- KRO Nasdaq
- PVLA Nasdaq
- Market Cap
- KRO 590.2M
- PVLA 604.2M
- IPO Year
- KRO N/A
- PVLA N/A
- Fundamental
- Price
- KRO $4.35
- PVLA $77.89
- Analyst Decision
- KRO Strong Sell
- PVLA Strong Buy
- Analyst Count
- KRO 2
- PVLA 13
- Target Price
- KRO $6.50
- PVLA $93.00
- AVG Volume (30 Days)
- KRO 302.8K
- PVLA 171.6K
- Earning Date
- KRO 11-06-2025
- PVLA 11-11-2025
- Dividend Yield
- KRO 4.54%
- PVLA N/A
- EPS Growth
- KRO N/A
- PVLA N/A
- EPS
- KRO N/A
- PVLA N/A
- Revenue
- KRO $1,864,200,000.00
- PVLA N/A
- Revenue This Year
- KRO N/A
- PVLA N/A
- Revenue Next Year
- KRO $6.29
- PVLA N/A
- P/E Ratio
- KRO N/A
- PVLA N/A
- Revenue Growth
- KRO 0.01
- PVLA N/A
- 52 Week Low
- KRO $4.08
- PVLA $11.17
- 52 Week High
- KRO $12.92
- PVLA $83.00
- Technical
- Relative Strength Index (RSI)
- KRO 28.44
- PVLA 59.88
- Support Level
- KRO $4.61
- PVLA $71.55
- Resistance Level
- KRO $4.79
- PVLA $82.35
- Average True Range (ATR)
- KRO 0.20
- PVLA 4.97
- MACD
- KRO -0.01
- PVLA -0.29
- Stochastic Oscillator
- KRO 18.70
- PVLA 66.67
About KRO Kronos Worldwide Inc
Kronos Worldwide Inc manufactures and sells titanium dioxide pigments. Titanium dioxide is a white inorganic pigment used in various products. The majority of Kronos' sales come from titanium dioxide used for coatings on automobiles, aircraft, machines, appliances, traffic paint, and in both commercial and residential interiors and exteriors. The second product category is titanium dioxide used for plastics such as packaging materials and food packaging, houseware, appliances, toys, and computer cases. The majority of revenue comes from the United States.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.